SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sim1 who wrote (627)10/22/2000 1:27:24 PM
From: lrb  Read Replies (1) of 666
 
<<The Food & Drug Administration is expected to approve Bexxar in November>>

I've been confused by the discussion of the status of Coulter's BLA and its relation to the potential acquisition of Coulter by Corixa. Some of the reports, like this one, have seemed to me to suggest that CRXA will be able to withdraw its offer if Bexxar is not approved.

Is it not true that what the FDA will approve or disapprove in November is the application, not Bexxar, and that if Bexxar itself is finally approved, that will come after the CLTR/CRXA deal is consummated or dissolved?

-- Larry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News